Funding Secured from the Bill & Melinda Gates Foundation Focuses on Developing Next Generation Device for Long-Term Therapy Delivery ASHLAND, Mass., Nov. 22, 2024 /PRNewswire/ -- BioSurfaces is pleased to announce that the company has been awarded a $2.06 million grant from the Bill & Melinda Gates Foundation. This one-year grant focuses on advancing the development of BioSurfaces' Bio-Spun™ Cell Chamber (BSCC), an innovative device designed to provide long-term delivery of a biotherapeutic

SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced the pricing of its "reasonable best efforts" public offering with participation from the CEO and existing and new healthcare focused investors for the purchase and sale of up to 40,000,000 shares of common stock an

BALDWIN PARK, Calif., Nov. 22, 2024 /PRNewswire/ -- StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its HPC, Cord Blood product REGENECYTE ™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders. With this approval, StemCyte became the 15th company to receive BLA approval in 2024 and the first com

Supporting critical pediatric cancer research and providing hope for the 47 children diagnosed with cancer every day in the U.S. ATLANTA, Nov. 22, 2024 /PRNewswire/ -- On Friday, November 15, Rally Foundation for Childhood Cancer Research hosted its 17th Annual Benefit Bash. Delta Air Lines was the title sponsor and Altium Packaging and RTX were presenting sponsors. The night raised more than $3.7 million in critical funding for advances in childhood cancer. This milestone brings the total funds

DUBLIN--( BUSINESS WIRE )--The "Active Pharmaceutical Ingredients (API) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering. The global Active Pharmaceutical Ingredients (API) market is estimated at US$240.8 billion in 2024 and is expected to record a CAGR of 6.2% during the 2024-2030 analysis period and stand at a projected US$345.5 billion by 2030. This global report on Active Pharmaceutical Ingredients (API) analyzes the market based on Type, synthesis, manu

Implementing Strategic Restructuring to Eliminate Commercial Organization and Rationalize Operations Across All Functions Prioritizing Strong R&D Pipeline Including Ongoing Studies in DPNP, HCM and Obesity Efforts Expected to Reduce 2025 Operating Costs by $100 Million Conference Call and Webcast at 9:00 am ET THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate it

Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical management decisions in over 90% of leptomeningeal metastases (LM) cases Assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology AUSTIN, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), will present data from the FO

NASHVILLE, Tenn., Nov. 22, 2024 /PRNewswire/ -- Medalogix, the leading machine learning and AI company specializing in clinical decision support and advancement of patient care in home health and hospice, and strategic payor initiatives in the home, today announced the general availability of the new data science model for Pulse Transitions, formerly known as Bridge. Medalogix is the leading mortality risk solution for Home Health providers, already providing patient insights for more than 10% o

PCI Pharma Services (PCI) a global contract development and manufacturing organisation (CDMO) focused on biopharma’s most complex therapies – is collaborating with theranostics specialist ChiRhoClin to avoid the potential shortage of a critical diagnostic drug used to test for pancreatic disease and cancer. Following a high-priority project executed along a tight timeline, an ample, stable supply of ChiRhoStim (Human Secretin for Injection) continues to be available to benefit patients throughou

The Senate Judiciary Committee narrowly advanced a bill Thursday that would change the way the Patent Trial and Appeal Board operates, limiting the ability of parties to challenge patents in court and before the board at the same time. The bill barely passed by a vote of 11-10, with Republicans largely voting against it. Patient advocates say the bill would halt an additional path for patent challenges by generic drug competitors and potentially raise prices. “I can’t support something that’s go